Chief Quality Officer and Executive Vice President, Translational Sciences · Ultragenyx Pharmaceutical Inc. (RARE)

John Pinion

A named executive officer of Ultragenyx Pharmaceutical in every fiscal year CompBrief holds from FY2017 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$4,129,753

Salary $570,366Stock awards $2,084,548

FY2022: $3,706,511

5th of 5 named executive officers at Ultragenyx Pharmaceutical by FY2024 total.

5 named officers on file for Ultragenyx Pharmaceutical, FY2024

John Pinion’s pay file — $29

  • 7 fiscal years of pay, line by line
  • 16 equity grants, each cited to its filing
  • RARE’s disclosed peer group of 19 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Ultragenyx Pharmaceutical’s whole pay program stands against its peers

  • Ultragenyx Pharmaceutical’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on RARE→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed March 28, 2025 (DEF 14A).

Free

Get John Pinion’s full pay file as a PDF — free

More than this page: up to 10 years of John’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

John Pinion compensation by year

Ultragenyx Pharmaceutical Summary Compensation Table · all 7 fiscal years held
In US dollars, as Ultragenyx Pharmaceutical reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018FY2019FY2020FY2021FY2022FY2024
Salary$412,568$430,320$447,690$480,063$509,939$533,315$570,366
Bonus$0$0$0$0$0$0$0
Stock awards$308,603$217,935$1,756,300$723,432$1,653,212$2,007,768$2,084,548
Option awards$991,208$728,443$923,578$707,007$866,427$892,550$1,121,271
Non-equity incentive$170,459$188,030$205,490$267,138$224,942$260,678$339,768
Pension and deferred compensation$0$0$0$0$0$0$0
All other$36,491$0$37,472$0$8,700$12,200$13,800
Total$1,919,329$1,564,878$3,370,530$2,177,640$3,263,220$3,706,511$4,129,753

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Ultragenyx Pharmaceutical Inc. DEF 14A filed March 28, 2025, accession 0001308179-25-000296, and prior-year filings.

How this page was built: the Ultragenyx Pharmaceutical Inc. filed document, accession 0001308179-25-000296. Every figure is read from that document and cited to the page and table it appears in. Filed March 28, 2025.

$1.9M
$1.6M
$3.4M
$2.2M
$3.3M
$3.7M
$4.1M
FY17
FY18
FY19
FY20
FY21
FY22
FY24
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU31,471$1,323,985—
RSU17,800$748,846—
PSU17,800$748,846—
RSU10,472$440,557—
PSU7,029$295,710—
RSU1,375$57,846—
Option22,162—$45.65
Option7,781—$67.37
Option687—$142.47
Option100,000—$2.31
Option31,400—$53.69

Per the Outstanding Equity Awards at Fiscal Year-End table in Ultragenyx Pharmaceutical Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Ultragenyx Pharmaceutical’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Emil KakkisPresident and Chief Executive Officer$13,717,687
Eric CrombezChief Medical Officer and Executive Vice President$4,298,223
Howard HornChief Financial Officer, Corporate Strategy and Executive Vice President$4,296,049
Erik HarrisChief Commercial Officer and Executive Vice President$4,295,813
John Pinion · this pageChief Quality Officer and Executive Vice President, Translational Sciences$4,129,753

The full Ultragenyx Pharmaceutical compensation record

free company brief

This page is one person within Ultragenyx Pharmaceutical's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Ultragenyx Pharmaceutical proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Ultragenyx Pharmaceutical's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

John Pinion's compensation dossier · One-time report. No refunds.